Amgen’s Romiplostim Study: A Potential Breakthrough in Cancer Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. is conducting a pivotal study titled ‘PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer.’ The study aims to assess the effectiveness of romiplostim in managing chemotherapy-induced thrombocytopenia (CIT), focusing on enabling timely and full-dose chemotherapy administration in patients with NSCLC, ovarian cancer, or breast cancer.

The intervention being tested is romiplostim, an experimental drug administered via subcutaneous injection. It is designed to address CIT, a common side effect of chemotherapy that leads to low platelet counts, potentially disrupting cancer treatment schedules.

This interventional study employs a randomized, parallel assignment model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary goal is treatment, with a structured timeline including a screening period, treatment cycles, and follow-up phases.

The study began on February 26, 2020, with its primary completion and estimated full completion dates yet to be announced. The latest update was submitted on August 13, 2025, indicating ongoing recruitment and data collection.

Amgen’s progress in this study could influence its stock performance positively, as successful results may enhance its portfolio in the oncology sector. Investors should watch for developments, especially considering the competitive landscape in cancer treatment innovations.

The study is currently recruiting, with further details available on the ClinicalTrials portal.